The fund has no specific favorite in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Biotechnology, Software. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Centerline Biomedical, Numerate
The usual cause for the fund is to invest in rounds with 1 partaker. Despite the National Heart, Lung and Blood Institute, startups are often financed by National Institutes of Health, U.S. Department of Defense, MedTech Innovator. In the next rounds fund is usually obtained by National Institutes of Health, National Cancer Institute.
Deals in the range of 5 - 10 millions dollars are the general things for fund. The high activity for fund was in 2019. The fund is constantly included in 2-6 investment rounds annually.
| Fund Name | Location |
| 57 Stars | District of Columbia, United States, Washington |
| Anyuan Fund | Anhui, China, Hefei |
| Avista Partners | England, London, United Kingdom |
| Baleine & Bjorn Capital | New York, New York, United States |
| CCBI Tech Venture | China, Jiangsu, Suzhou |
| CLEARTH LIFE | Japan, Minato |
| Club Digitale | Italy, Lombardia, Milano |
| Coventry Asset Management. | - |
| IRDI | France, Occitania, Toulouse |
| IVAC Fund | - |
| SEB Alliance | Écully, France, Rhone-Alpes |
| Staidson Hongkong Investment | China, Hong Kong, Hong Kong Island |
| Sulzer Chemtech | Switzerland, Winterthur, Zurich |
| Tanggula Touzi | Beijing, Beijing, China |
| Tele2 | - |
| Thorney Investment | Australia, Melbourne, Victoria |
| Tsinghua Automotive Research Institute | China, Jiangsu, Suzhou |
| Wadi Jeddah Venture | - |
| Wingspring Ventures | California, Palo Alto, United States |
| Zheke Investment | China, Hangzhou, Zhejiang |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 